WCN24-2290 A novel approach to induce early remission in high-risk primary membranous nephropathy

A considerable proportion of primary membranous nephropathy (PMN) patients do not achieve early clinical remission with current immunosuppression regimens. Our objective was to develop a novel multitargeted approach for the induction of early remission to prevent life-threatening complications of nephrotic syndrome. We demonstrate a highly efficacy and safety of "never-used-before" treatment regimen including rituximab, cyclophosphamide, and corticosteroids at low cumulative doses (RCP) in high-risk PMN patients.